Evolving Fertility Care Coverage in the U.S.: Legislative Updates for 2025
The landscape of fertility care coverage in the United States is rapidly evolving as state and federal lawmakers intensify their focus on this critical issue in 2025. Recent debates have centered around enhancing affordability and access to fertility treatments, such as in vitro fertilization (IVF) and fertility preservation. Currently, 25 states and Washington, D.C. mandate private insurance coverage for fertility care, though requirements vary significantly regarding criteria and coverage types.
Typically, fertility coverage includes infertility diagnosis, assistance with underlying causes, and fertility-preserving technologies. State laws may impose conditions such as age limits, marital status, or specific medical criteria for eligibility. Importantly, numerous states require coverage for fertility preservation only when infertility stems from necessary medical treatments like chemotherapy.
Medicaid presents a more limited landscape for fertility treatment coverage compared to private insurance. New York, Utah, and Washington, D.C. offer restricted Medicaid coverage for infertility, with New York and Washington, D.C. limiting it to three cycles of ovulation-inducing medications. Utah's 2024 amendment allows IVF and genetic testing coverage, specifically for genetic disease carriers, while five states cover fertility preservation for treatments causing infertility.
Over half of the states are actively considering legislation related to fertility care coverage, either through new proposals or ongoing legislative actions. Commercial insurance markets are experiencing more legislative activity than Medicaid, with a focus on refining benefit designs and expanding access within budget constraints.
State Initiatives and Legislative Developments
In Virginia, the General Assembly passed VA HB 328, revising its essential health benefits plan by 2028 to include treatment for iatrogenic infertility and assisted reproductive technology for up to three cycles per lifetime. This followed a recommendation by the state's Health Insurance Reform Commission.
Arizona and Hawaii are moving forward with legislation targeting coverage for individuals at risk of iatrogenic infertility. Arizona's Senate passed AZ SB 1347, mandating insurers to cover fertility preservation services for cancer patients. Hawaii's House approved a similar measure, HI HB 1684, with both awaiting further legislative action. Conversely, Idaho opted against advancing a related proposal, ID HB 818.
Rhode Island and Connecticut have taken exploratory steps, with Rhode Island proposing HR 7951 to study women's reproductive health services, while Connecticut's HB 5374 transitioned from a study directive to a bill for expanded insurance coverage definitions. These legislative efforts highlight a national trend towards incremental changes in fertility coverage that could necessitate strategic adjustments from health organizations nationwide.